Spigel David R, Mekhail Tarek M, Waterhouse David, Hadley Terence, Webb Charles, Burris Howard A, Hainsworth John D, Greco F Anthony
a Sarah Cannon Research Institute/Tennessee Oncology, PLLC , Nashville , Tennessee , USA.
b Florida Hospital Cancer Institute , Orlando , Florida , USA.
Cancer Invest. 2017 Sep 14;35(8):541-546. doi: 10.1080/07357907.2017.1344698. Epub 2017 Aug 1.
We added panitumumab to standard combination chemotherapy as first-line treatment for patients with advanced KRAS WT non-squamous NSCLC.
Patients received panitumumab 9 mg/kg IV, pemetrexed 500 mg/m IV, and carboplatin AUC = 6 IV every 21 days. After 6 cycles, maintenance therapy with panitumumab and pemetrexed was administered every 21 days until progressive disease or unacceptable toxicity.
29 of 66 patients (44%) had objective responses. The median TTP was 6 months; median overall survival (OS) was 17 months. Panitumumab increased treatment-related toxicity, notably skin rash.
The addition of panitumumab increased toxicity, and had no discernible impact on efficacy.
我们将帕尼单抗添加至标准联合化疗方案中，作为晚期KRAS野生型非鳞状非小细胞肺癌患者的一线治疗。
患者接受静脉注射帕尼单抗9mg/kg、培美曲塞500mg/m²静脉注射以及卡铂AUC = 6静脉注射，每21天一次。6个周期后，每21天给予帕尼单抗和培美曲塞维持治疗，直至疾病进展或出现不可接受的毒性。
66例患者中有29例（44%）出现客观缓解。中位疾病进展时间为6个月；中位总生存期为17个月。帕尼单抗增加了治疗相关毒性，尤其是皮疹。
添加帕尼单抗增加了毒性，且对疗效无明显影响。
